Clobetasone: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
m (Protected "Clobetasone": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)))
 
(5 intermediate revisions by 3 users not shown)
Line 1: Line 1:
{{drugbox |
{{Drugbox
| IUPAC_name = (''8S,9R,10S,13S,14S,16S,17R'')-17-(2-Chloroacetyl)-9-fluoro-17-hydroxy-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-''6H''-cyclopenta[a]phenanthrene-3,11-dione
| Watchedfields = changed
| verifiedrevid = 447609987
| IUPAC_name = (1''R'',2''S'',10''S'',11''S'',13''S'',14''R'',15''S'')-14-(2-chloroacetyl)-1-fluoro-14-hydroxy-2,13,15-trimethyltetracyclo[8.7.0.0<sup>2,7</sup>.0<sup>11,15</sup>]heptadeca-3,6-diene-5,17-dione
| image = clobetasone.png
| image = clobetasone.png
<!--Clinical data-->
| tradename = Eumovate
| Drugs.com = {{drugs.com|CONS|clobetasone}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4  / S8 -->
| legal_UK = <!-- GSL        / P      / POM / CD -->
| legal_US = <!-- OTC                  / Rx-only  -->
| legal_status = 
| routes_of_administration = topical
<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 54063-32-0
| CAS_number = 54063-32-0
| ATC_prefix = D07
| ATC_prefix = D07
| ATC_suffix = AB01
| ATC_suffix = AB01
| ATC_supplemental = {{ATC|S01|BA09}}
| ATC_supplemental = {{ATC|S01|BA09}}
| PubChem = 71387
| PubChem = 71387
| DrugBank =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 64482
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = LT69WY1J6D
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07717
 
<!--Chemical data-->
| C=22 | H=26 | Cl=1 | F=1 | O=4  
| C=22 | H=26 | Cl=1 | F=1 | O=4  
| molecular_weight = 408.891
| molecular_weight = 408.891 g/mol
| bioavailability =  
| smiles = ClCC(=O)[C@@]2(O)[C@@H](C)C[C@H]1[C@H]4[C@](F)(C(=O)C[C@@]12C)[C@@]/3(/C(=C\C(=O)\C=C\3)CC4)C
| protein_bound =  
| InChI = 1/C22H26ClFO4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-16,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,19-,20-,21-,22-/m0/s1
| metabolism =  
| InChIKey = XXIFVOHLGBURIG-OZCCCYNHBL
| elimination_half-life =  
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| excretion =  
| StdInChI = 1S/C22H26ClFO4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-16,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,19-,20-,21-,22-/m0/s1
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| pregnancy_US =  <!-- A / B            / C / D / X -->
| StdInChIKey = XXIFVOHLGBURIG-OZCCCYNHSA-N
| pregnancy_category =
| synonyms = (8''S'',9''R'',10''S'',13''S'',14''S'',16''S'',17''R'')-17-(2-Chloroacetyl)-9-fluoro-17-hydroxy-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6''H''-cyclopenta[''a'']phenanthrene-3,11-dione
| legal_AU =     <!-- Unscheduled / S2 / S3 / S4  / S8 -->
| legal_UK =      <!-- GSL        / P      / POM / CD -->
| legal_US =      <!-- OTC                  / Rx-only  -->
| legal_status =  
| routes_of_administration = topical
}}
}}
{{EH}}
__NOTOC__
{{SI}}
{{CMG}}
==Overview==
'''Clobetasone''' ([[International Nonproprietary Name|INN]]) is a [[corticosteroid]] used in [[dermatology]], for treating such skin inflammation as seen in [[eczema]], [[psoriasis]] and other forms of [[dermatitis]], and [[ophthalmology]].  Topical clobetasone butyrate has shown minimal suppression of the [[Hypothalamic-pituitary-adrenal axis]].
 
It is available as clobetasone butyrate under the brand names '''Eumosone''' or '''Eumovate''' both manufactured by [[GlaxoSmithKline]].


'''Clobetasone''' is a [[corticosteroid]] used in [[dermatology]], for treating such skin inflammation as seen in [[eczema]] and other forms of [[dermatitis]], and [[ophthalmology]].
'''Trimovate''' also contains [[Oxytetracycline]], an [[antibiotic]], and [[nystatin]], an [[Antifungal medication|antifungal]].


It is available as clobetasone butyrate under the brand name '''Eumovate''' manufactured by [[GlaxoSmithKline]].
==Uses==
In [[dermatology]], topical clobestasone butyrate helps to reduce the itchiness and [[erythema]] associated with [[eczema]] and [[dermatitis]].
In [[ophthalmology]], clobetasone butyrate 0.1% eye drops have been shown to be safe and effective in the treatment of dry eyes in [[Sjögren's Syndrome]]. Sjögren's Syndrome is an autoimmune disorder that affects the moisture producing glands of the body causing many symptoms including dry eyes. When compared to other corticosteroid eye drops; clobetasone butyrate showed only minimal rises in intraocular pressure. Increased pressure within the eye can lead to [[glaucoma]].


{{Corticosteroids}}
==Adverse effects==
{{SIB}}
Side effects associated with clobetasone cream and ointment include: burning, irritation, itching, thinning of the skin, and changes in skin color.


{{treatment-stub}}
==References==
{{Reflist|2}}


[[Category:Corticosteroids]]
[[Category:Corticosteroids]]
[[Category:Organohalides]]
[[Category:Organochlorides]]
{{WikiDoc Help Menu}}
[[Category:Organofluorides]]
{{WS}}
[[Category:Alcohols]]
[[Category:Ketones]]
[[Category:Drug]]

Latest revision as of 19:14, 18 August 2015

Clobetasone
Clinical data
Trade namesEumovate
Synonyms(8S,9R,10S,13S,14S,16S,17R)-17-(2-Chloroacetyl)-9-fluoro-17-hydroxy-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthrene-3,11-dione
AHFS/Drugs.comMicromedex Detailed Consumer Information
Routes of
administration
topical
ATC code
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC22H26ClFO4
Molar mass408.891 g/mol
3D model (JSmol)
  (verify)

WikiDoc Resources for Clobetasone

Articles

Most recent articles on Clobetasone

Most cited articles on Clobetasone

Review articles on Clobetasone

Articles on Clobetasone in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Clobetasone

Images of Clobetasone

Photos of Clobetasone

Podcasts & MP3s on Clobetasone

Videos on Clobetasone

Evidence Based Medicine

Cochrane Collaboration on Clobetasone

Bandolier on Clobetasone

TRIP on Clobetasone

Clinical Trials

Ongoing Trials on Clobetasone at Clinical Trials.gov

Trial results on Clobetasone

Clinical Trials on Clobetasone at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Clobetasone

NICE Guidance on Clobetasone

NHS PRODIGY Guidance

FDA on Clobetasone

CDC on Clobetasone

Books

Books on Clobetasone

News

Clobetasone in the news

Be alerted to news on Clobetasone

News trends on Clobetasone

Commentary

Blogs on Clobetasone

Definitions

Definitions of Clobetasone

Patient Resources / Community

Patient resources on Clobetasone

Discussion groups on Clobetasone

Patient Handouts on Clobetasone

Directions to Hospitals Treating Clobetasone

Risk calculators and risk factors for Clobetasone

Healthcare Provider Resources

Symptoms of Clobetasone

Causes & Risk Factors for Clobetasone

Diagnostic studies for Clobetasone

Treatment of Clobetasone

Continuing Medical Education (CME)

CME Programs on Clobetasone

International

Clobetasone en Espanol

Clobetasone en Francais

Business

Clobetasone in the Marketplace

Patents on Clobetasone

Experimental / Informatics

List of terms related to Clobetasone

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Clobetasone (INN) is a corticosteroid used in dermatology, for treating such skin inflammation as seen in eczema, psoriasis and other forms of dermatitis, and ophthalmology. Topical clobetasone butyrate has shown minimal suppression of the Hypothalamic-pituitary-adrenal axis.

It is available as clobetasone butyrate under the brand names Eumosone or Eumovate both manufactured by GlaxoSmithKline.

Trimovate also contains Oxytetracycline, an antibiotic, and nystatin, an antifungal.

Uses

In dermatology, topical clobestasone butyrate helps to reduce the itchiness and erythema associated with eczema and dermatitis. In ophthalmology, clobetasone butyrate 0.1% eye drops have been shown to be safe and effective in the treatment of dry eyes in Sjögren's Syndrome. Sjögren's Syndrome is an autoimmune disorder that affects the moisture producing glands of the body causing many symptoms including dry eyes. When compared to other corticosteroid eye drops; clobetasone butyrate showed only minimal rises in intraocular pressure. Increased pressure within the eye can lead to glaucoma.

Adverse effects

Side effects associated with clobetasone cream and ointment include: burning, irritation, itching, thinning of the skin, and changes in skin color.

References